New video features patient voices.

A new video from Hikma Community Health™* is a collection of comments researchers captured in 2021 while conducting the MORE study, which showed multiple naloxone doses are often involved in opioid overdose reversal incidents.¹

The 3-minute video features six testimonials from people with experience using naloxone HCI nasal spray 4mg, including a man in his early 40s reflecting on a personal overdose incident and a woman in her mid 40s who says while reflecting on an overdose incident involving a friend, “Sometimes with [illicitly manufactured] fentanyl, it takes more than just one dose of it to work…I’m confident if I have [naloxone] on me and somebody’s overdosing that it will help.”

About the study

Hikma researchers asked 125 US residents who had given Narcan® Nasal Spray to another person in the past year to take part in a web-based survey. The investigators then asked 35 participants to complete an open-ended voice survey. The voices included on the video explain a strong preference and greater confidence in an 8mg naloxone nasal spray than a 4mg naloxone nasal spray.¹

Kloxxado® (naloxone HCl) Nasal Spray 8 mg contains double the dose per spray compared to a Narcan® 4mg nasal spray. Because bystanders may be the first on site to administer naloxone to someone having an opioid overdose, it is critical for them to have access to enough naloxone to reverse the overdose.¹

Kloxxado® is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adult and pediatric patients.² Kloxxado® provides twice as much medication per spray compared to other currently available naloxone intranasal formulations.²,³

The full prescribing information for Kloxxado® includes a number of warnings and precautions common to naloxone products.² These include risk of recurrent respiratory and CNS depression, risk of limited efficacy with partial agonists or mixed agonist/antagonists, precipitation of severe opioid withdrawal and risk of cardiovascular effects.²

Important Safety Information about Kloxxado® is located in the grey section below. You can find the full PI here.

*Hikma Community Health is a subsidiary of Hikma Specialty USA Inc., a leading provider of quality oral, liquid, inhalant and injectable branded and non-branded generic medicines in the United States.

Real-World Study of Multiple Naloxone Administration for Opioid Overdose Reversal Among Bystanders

Hikma Community Health™ is a trademark of Hikma Pharmaceuticals USA Inc.

Narcan® is a registered trademark of Emergent Operations Ireland, Ltd.

Kloxxado® is a registered trademark of Hikma Pharmaceuticals USA Inc. Please see the full Prescribing Information and Medication Guide for Kloxxado® for complete product details.

NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.



  1. Abdelal R, Banerjee A, Carlberg-Racich S, Darwaza N, Ito D, Shoaff J, Epstein J. Real-World Study of Multiple Naloxone Administration for Opioid Overdose Reversal Among Bystanders. JMCP. 2021;27(10-a):S54.
  2. Kloxxado® (naloxone HCl) nasal spray 8 mg [prescribing information]. Columbus, OH: Hikma Pharmaceuticals USA Inc.; 2021.
  3. Narcan® (naloxone HCl) nasal spray 4 mg [prescribing information]. Plymouth Meeting, PA: Emergent Devices Inc.; 2021.